Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022

Rhea-AI Summary

Delcath Systems (DCTH), an interventional oncology company, has announced its participation in the H.C. Wainwright BioConnect Virtual Investor Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Delcath will also hold one-on-one investor meetings during the event. The company focuses on innovative treatments for liver cancers, utilizing its proprietary percutaneous hepatic perfusion system, HEPZATO, in the U.S. and CHEMOSAT in Europe.

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:

• H.C. Wainwright BioConnect Virtual Investor Conference January 10-13, 2022
  • Presentation Date and Time: On-demand beginning January 10, 2022 at 7:00 AM (ET)
  • Webcast: https://journey.ct.events/view/f57806c5-e3e7-4120-85c6-37ab9b15d128
  • Management will also host 1x1 investor meetings during the conference.

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When will Delcath Systems participate in the investor conference?

Delcath Systems will participate in the H.C. Wainwright BioConnect Virtual Investor Conference from January 10-13, 2022.

What is the presentation date and time for Delcath Systems at the conference?

The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET.

How can I access the Delcath Systems presentation?

You can access the Delcath Systems presentation via the webcast link provided in their press release.

What treatment does Delcath Systems focus on?

Delcath Systems focuses on the treatment of primary and metastatic cancers of the liver using its proprietary PHP system.

What is the trade name of Delcath Systems' product in the U.S.?

In the U.S., Delcath Systems' product is marketed under the trade name HEPZATO.